Ligritinib

Ligritinib
Clinical data
Other namesAB-801
Identifiers
  • 6-[(7S)-3-[3-[5-(3-methyl-2-pyridinyl)-2-pyridinyl]-2H-pyrazolo[3,4-b]pyridin-5-yl]-6,7,8,9-tetrahydro-5H-benzo[7]annulen-7-yl]-3-oxa-6-azabicyclo[3.1.1]heptane
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC33H32N6O
Molar mass528.660 g·mol−1
3D model (JSmol)
  • CC1=C(N=CC=C1)C2=CN=C(C=C2)C3=C4C=C(C=NC4=NN3)C5=CC6=C(CC[C@@H](CC6)N7C8CC7COC8)C=C5
  • InChI=InChI=1S/C33H32N6O/c1-20-3-2-12-34-31(20)24-8-11-30(35-16-24)32-29-14-25(17-36-33(29)38-37-32)23-5-4-21-6-9-26(10-7-22(21)13-23)39-27-15-28(39)19-40-18-27/h2-5,8,11-14,16-17,26-28H,6-7,9-10,15,18-19H2,1H3,(H,36,37,38)/t26-,27?,28?/m0/s1
  • Key:IANIKXYKEWAAKX-XWYKLZMASA-N

Ligritinib is an investigational new drug that is being developed by Arcus Biosciences for the treatment of pancreatic adenocarcinoma, cholangiocarcinoma, and other solid tumors. It is an AXL receptor tyrosine kinase inhibitor.

References

  1. ↑ "Ligritinib". AdisInsight. Springer Nature Switzerland AG. Retrieved 3 July 2026.
  2. ↑ Miles DH, Lamani M, Paladugu SR, Qu S, Foley CN, Sharif EU, et al. (June 2025). "Discovery of AB801, a Potent and Selective Inhibitor of AXL Receptor Tyrosine Kinase for Use in Cancer Therapy". Journal of Medicinal Chemistry. 68 (11): 10663–10676. doi:10.1021/acs.jmedchem.5c00239. PMID 40407274. Compound 37